Trials / Completed
CompletedNCT03845400
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 168 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.
Conditions
Timeline
- Start date
- 2019-03-30
- Primary completion
- 2022-10-22
- Completion
- 2022-10-22
- First posted
- 2019-02-19
- Last updated
- 2023-03-30
Locations
29 sites across 3 countries: United States, Canada, Puerto Rico
Source: ClinicalTrials.gov record NCT03845400. Inclusion in this directory is not an endorsement.